Menu
Explore Our Trials
Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.
Results 31-40 of 59
Blood Cancer
Enhancing the metabolic function of CAR T cells for lymphoma
Enhancing the metabolic function of CAR T cells for lymphoma Summary: CAR T-cell therapy has changed the treatment paradigms of relapsed diffuse large B-cell lymphoma (DLBCL) by demonstrating long term durability in approximately 40% of treated patients. CAR T-cell therapy is when a patient’s own T-cells (white blood cells that kill cancer cells) are collected […]
Gunjan Shah, MD
Memorial Sloan Kettering Cancer Center
Brain Cancer
Phase I/II Study of Pamiparib (BGB-290) with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations
Phase I/II Study of Pamiparib (BGB-290) with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations Summary: IDH1/2 mutations are commonly found in adult gliomas. Gliomas with these mutations are thought to have a better prognosis than patients without the IDH1/2 mutations, but nearly all patients will eventually recur, and thus better options are needed. A recent […]
Ranjit Bindra, MD, PhD
Yale University
Head/Neck Cancer
A randomized phase 2 study of local ablation with stereotactic body radiotherapy (SBRT) for patients with oligometastatic adenoid cystic carcinoma (ACC)
A randomized phase 2 study of local ablation with stereotactic body radiotherapy (SBRT) for patients with oligometastatic adenoid cystic carcinoma (ACC) Summary: Adenoid cystic carcinoma (ACC) is a rare type of salivary gland tumor. Despite upfront aggressive treatment with surgery, radiation therapy, and/or chemotherapy, approximately 50% of patients develop distance metastases, and up to a […]
Jonathan Schoenfeld, MD, MPhil, MPH
Dana-Farber Cancer Institute
Solid Tumors
The Online Adaptation of Managing Cancer and Living Meaningfully (iCALM): A Phase II Randomized Controlled Trial
The Online Adaptation of Managing Cancer and Living Meaningfully (iCALM): A Phase II Randomized Controlled Trial Summary: Individuals and families living with advanced cancer face multiple challenges related to the disease and its treatment. These include managing distressing symptoms and side effects, navigating a complex healthcare system, making difficult treatment decisions, and planning for the […]
Gary Rodin, MD
University Health Network - Princess Margaret Cancer Centre
Solid Tumors
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors Summary: The protein, p53, is responsible for stopping cellular growth and inducing the self-destruction of unwanted cells. As a result, the gene encoding for p53, TP53, is classified as a tumor suppressor gene. Proteins such as MDM2 and MDMX can inhibit p53, […]
Ecaterina Dumbrava, MD
MD Anderson Cancer Center
Thyroid Cancer
Targeted Therapy Combined with Pembrolizumab in Anaplastic Thyroid Cancer: Two Phase II Clinical Trials
Targeted Therapy Combined with Pembrolizumab in Anaplastic Thyroid Cancer: Two Phase II Clinical Trials Summary: Anaplastic thyroid cancer (ATC) is a rare thyroid cancer representing less than 2% of all thyroid cancers. However, it is one of the most lethal human malignancies with a historical median survival of 3 months after diagnosis. Recent advances in […]
Mark Zafereo, MD, FACS
MD Anderson Cancer Center
Brain Cancer
Clinical evaluation of IL13Rα2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma
Clinical evaluation of IL13Rα2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma Summary: Malignant gliomas (MG) are highly aggressive tumors with 5-year survival rates historically less than 10%. Despite aggressive standard of care therapy with surgery, radiation, and chemotherapy, it is almost inevitable that the disease will relapse, and […]
Christine Brown, PhD
City of Hope Comprehensive Cancer Center
Lung Cancer
Phase 2 trial of the fatty acid synthase (FASN) inhibitor TVB-2640 for advanced KRAS mutant non-small cell lung cancer (NSCLC)
Phase 2 trial of the fatty acid synthase (FASN) inhibitor TVB-2640 for advanced KRAS mutant non-small cell lung cancer (NSCLC) Summary: Non-small cell lung cancer (NSCLC) with a mutation called KRAS occurs in approximately 40,000 patients in the U.S. each year. Patients with the KRAS mutation have a particularly poor prognosis with a 5-year survival […]
David Gerber, MD
University of Texas Southwestern Medical Center
Brain Cancer
A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL- 12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma
A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL- 12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma Summary: Gliomas are the most common brain tumor, with glioblastoma multiforme (GBM) being one of the most fatal and treatment-resistant cancers. Survival and time to progression have changed minimally in […]
James Markert, MD, MPH
University of Alabama at Birmingham
All Cancers
Mitochondrial-Targeted Gamitrinib for Cancer Therapy
Mitochondrial-Targeted Gamitrinib for Cancer Therapy Summary: There have been impressive clinical responses in select tumors to targeted therapy, but for most cancers the gains are short-lived, and the cancer progresses. It has been found that a protein called Hsp90 chaperone is over abundant in cancer cells. The Hsp90 chaperones are responsible for stabilizing proteins and […]
Dario Altieri, MD
The Wistar Institute
